A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Completed · Phase 1
Conditions studied: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
In brief
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel. Patients will receive increasing doses of study drug in combination with paclitaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 36 patients from the US will be enrolled in this study.
Key facts
- Study ID
- NCT01649336
- Run by
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- People needed
- 36
- Starts
- 2012-07-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2020-09-14
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Pfizer Investigational Site — Scottsdale, Arizona, United States
- Pfizer Investigational Site — Lafayette, Indiana, United States
- Pfizer Investigational Site — New York, New York, United States
- Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.